• Recruiting

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for ASCT in Myeloma (CarMob)

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)

carmob - carfilzomib mobilization

NCT03909412: Phase 1: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma (CarMob)


This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)


Sponsor

Hackensack Meridian Health


Collaborator

Amgen

 

ClinicalTrials.gov Identifier: NCT03909412

Official Title: Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma

First Posted : April 10, 2019

Click here to see details on ClinicalTrials.gov

 

Carfilzomib : National Cancer Institute

Carfilzomib : MedlinePlus Drug Information

 

Drug: Carfilzomib

Drug: Cyclophosphamide

Drug: Dexamethasone

Drug: Granulocyte Colony-Stimulating Factor

 

Location

United States, New Jersey

Hackensack Meridian Health - John Theurer Cancer Center


Posts Archive